CXCR3 and systemic sclerosis: In conclusion, we were able to demonstrate that aabs against CXCR3 in SSc patient sera show a different binding pattern like healthy control sera, with increased binding to intracellular epitopes and loss of binding to the extracellular N-terminal rod domain.